Elite Pharmaceuticals Reports Positive Results from a Pivotal Bioequivalence Study
NORTHVALE, NJ / ACCESSWIRE / August 28, 2023 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company")(OTCQB:ELTP), a specialty pharmaceutical company...
Pharmaceutical
iZafe Group’s CEO Anders Segerström Acquires an Additional 208,333 Shares
STOCKHOLM, SWEDEN / ACCESSWIRE / August 28, 2023 / iZafe Group (STO:IZAFE-B.ST) iZafe Group's CEO, Anders Segerström, has today acquired...
BridgeBio presents detailed positive results from Phase 3 ATTRibute-CM study of acoramidis for patients with transthyretin amyloid cardiomyopathy (ATTR-CM) at European Society of Cardiology Congress 2023
- The primary endpoint was met (Win Ratio of 1.8) with a highly statistically significant p-value (p<0.0001); this primary endpoint...
Assertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
LAKE FOREST, Ill., Aug. 25, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT), a specialty...
GE HealthCare Introduces Vscan Air SL, a Wireless Handheld Ultrasound Device for Rapid Assessments of Cardiac and Vascular Patients
With a dual-headed probe, the Vscan Air SL offers a sector array and a linear array on a single device...
IIOT-OXYS, Inc. Reports 2023 Form 10-Q Second Quarter Results and Upcoming Investor Conference Call
CAMBRIDGE, MA / ACCESSWIRE / August 25, 2023 / IIOT-OXYS, Inc. (OTC PINK:ITOX) ("Oxys" or the "Company") announced its financial...
Correction: iZafe Group Q2 Interim Report, April-June 2023
The MAR stamp was mistakenly not included in the initial PM.STOCKHOLM, SE / ACCESSWIRE / August 25, 2023 / iZafe...
iZafe Group Q2 Interim Report, April-June 2023
STOCKHOLM, SE / ACCESSWIRE / August 25, 2023 / iZafe Group (STO:IZAFE-B) iZafe Group AB (publ.) presents today, August 25,...
Acenzia Selected to join Team Canada Trade Mission to India
Team Canada Delegation to be led by Honorable Mary Ng, Canada’s Minister of International Trade, Export Promotion, Small Business and...
GE HealthCare Launches CardioVisio for Atrial Fibrillation, a Digital, Patient-Centric Clinical Decision Support Tool to Enable Precision Care
Integrating and analyzing data over time and across various data sources, CardioVisio for Atrial Fibrillation helps visualize the history of...
iZafe Group’s New Identity is Launched to Clarify the Company’s Vision
STOCKHOLM, SWEDEN / ACCESSWIRE / August 24, 2023 / iZafe Group (STO:IZAFE-B) iZafe group AB (publ.) is proud to present...
GE HealthCare Management to Present at September Investor Conferences
CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC), is announcing today that members of its senior management team will be presenting at the...
BioHarvest Sciences to Host Virtual Shareholder Presentation September 6, 2023
Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - August 24, 2023) - BioHarvest Sciences Inc. (CSE: BHSC) (OTCQB: CNVCF) ("BioHarvest" or the...
Jaguar Health Engages B2i Digital to Deploy Cutting-Edge Investor Engagement Campaign
Jaguar aims to leverage digital technologies including AI enhancement to help connect with investor communitiesSAN FRANCISCO, CA / ACCESSWIRE /...
Now Available – XDEMVY™ (lotilaner ophthalmic solution) 0.25%, the First and Only FDA Approved Treatment for Demodex Blepharitis
Demodex blepharitis impacts approximately 25 million eye care patients in the U.S. – or 1 out of every 12 adults. XDEMVY...
The International Myeloma Foundation (IMF) Amplifies #kNOwMyeloma Campaign for Blood Cancer Awareness Month 2023
LOS ANGELES, Aug. 24, 2023 (GLOBE NEWSWIRE) -- In 2010, the U.S. Congress designated September as Blood Cancer Awareness Month...
MiNK Therapeutics to Participate in September Investor Conferences
NEW YORK, Aug. 24, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics (Nasdaq: INKT), a clinical-stage biopharmaceutical company specializing in the discovery,...
Verrica Pharmaceuticals Announces First Sale of YCANTH™ to FFF Enterprises
YCANTH™ is the first and only FDA-approved treatment for molluscum, a highly contagious viral skin infection affecting approximately 6 million...
AEON Biopharma Receives Notice of Allowance from USPTO for a Patent Covering Use of Botulinum Toxins to Treat Migraine Headache
IRVINE, Calif., Aug. 24, 2023 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON, AEON WS), a...
Recce Pharmaceuticals Doses Patients in Phase I/II Clinical Trial of RECCE® 327 for Diabetic Foot Infections
Patients dosed in Phase I/II trial, evaluating RECCE® 327 (R327) in patients with diabetic foot infections (DFI), currently the largest...